BioTuesdays

Tag - Jason McCarthy

BioLife Logo
Markets

Maxim ups Biolife Solutions PT to $26 from $18

Maxim Group raised its price target for Biolife Solutions (NASDAQ:BLFS) to $26 from $18, citing a strengthening balance sheet, with management continuing to execute on its growth strategy. The stock closed at $17.59 on...

July 8, 2020
Onconova Logo
Markets

Maxim ups Onconova Therapeutics to buy; PT $1.25

Maxim Group upgraded Onconova Therapeutics (NASDAQ:ONTX) to “buy” from “hold” with a new price target of $1.25, citing a strengthened balance sheet, and a sufficient cash runway into the third quarter of 2021, well past...

May 15, 2020
Artelo Biosciences Logo
Markets

Maxim cuts Artelo Biosciences to hold and removes PT

Maxim Group downgraded Artelo Biosciences (NASDAQ:ARTL) to “hold” from “ buy” without a price target, citing capital concerns. The stock closed at $1.22 on May 12, near the low end of its 52-week range of 61 cents to...

May 13, 2020
AIM ImmunoTech
Markets

Maxim ups AIM ImmunoTech PT to $5 from $2

Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five...

April 6, 2020
Co-Diagnostics
Markets

Maxim cuts Co-Diagnostics to hold; removes PT

Maxim Group downgraded Co-Diagnostics (NASDAQ:CODX) to “hold” from “buy” and removed its price target, reflecting a meteoric rise in the company’s stock price in 2020. The stock closed at $17.81 on March 2. Analyst...

March 3, 2020
Agile Therapeutics
Markets

Maxim ups Agile Therapeutics PT to $8 from $3

Maxim Group raised its price target for Agile Therapeutics (NASDAQ:AGRX) to $8 from $3 after the FDA approved the company’s weekly contraceptive patch, Twirla. The stock closed at $4.07 on Feb. 14. Agile shares...

February 18, 2020
Co-Diagnostics
Markets

Maxim ups Co-Diagnostics PT to $5 from $2

Maxim Group raised its price target for Co-Diagnostics (NASDAQ:CODX) to $5 from $2, citing the company’s rapid development of a coronavirus test. The stock closed at $3.32 on Feb. 14. Analyst Jason McCarthy writes that...

February 18, 2020
Heat Biologics
Markets

Maxim starts Heat Biologics at buy; PT $1

Maxim Group launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and price target of $1. The stock closed at 26 cents on Feb. 5. Heat is developing lead asset, ImPACT, a cell-based immune therapy for...

February 6, 2020
Armata Pharmaceuticals
Markets

Maxim starts Armata Pharma at buy; PT $8

Maxim Group initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and $8 price target. The stock closed at $3.71 on Feb. 5. Armata is developing phage therapies for the treatment of...

February 6, 2020

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.